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The stromal vasculature in tumors is a vital conduit of nutrients and oxygen for cancer cells. To date, the vast
majority of studies have focused on unraveling the genetic basis of vessel sprouting (also termed angiogenesis).
In contrast to the widely studied changes in cancer cell metabolism, insight in the metabolic regulation of
angiogenesis is only just emerging. These studies show that metabolic pathways in endothelial cells (ECs)
importantly regulate angiogenesis in conjunction with genetic signals. In this review, we will highlight these
emerging insights in EC metabolism and discuss them in perspective of cancer cell metabolism. While it is generally
assumed that cancer cells have unique metabolic adaptations, not shared by healthy non-transformed cells, we will
discuss parallels and highlight differences between endothelial and cancer cell metabolism and consider possible
novel therapeutic opportunities arising from targeting both cancer and endothelial cells.
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Cancer cells are metabolically highly active and require
large supplies of nutrients. Blood vessels are vital to their
survival, as they not only supply oxygen and nutrients
but also remove metabolic waste. Tumors excessively
stimulate blood vessel growth to meet their metabolic
needs. Thus, a better understanding of how blood ves-
sels nourish tumors can offer novel therapeutic oppor-
tunities to prevent or reverse tumor progression. In the
past decades, antiangiogenic strategies were primarily
based on starving the tumor by destroying the vascular
supply through inhibition of key pro-angiogenic mole-
cules. Vascular endothelial growth factor (VEGF) is one
of the key regulators of angiogenesis and the prime
target of antiangiogenic drug development for the treat-
ment of multiple cancers [1,2]. However, insufficient
efficiency and resistance to VEGF-signaling blockade
strategies limit their overall success [2-5], necessitating
the development of alternative—mechanistically distinct—* Correspondence: peter.carmeliet@vib-kuleuven.be
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article, unless otherwise stated.strategies. We therefore proposed a new paradigm to
inhibit tumor growth or other angiogenic pathologies, one
that is based on starving the pathological (tumor) vessels
themselves from critical metabolic fuel and energy [6,7].
We postulated that when quiescent endothelial cells (ECs)
switch to rapid vessel sprouting (the so-called angiogenic
switch), they adapt their metabolism to generate ad-
ditional energy and biomass for growth and division. More
simply, the angiogenic switch also requires an ‘angiogenic
metabolic switch.’ We further hypothesized that metabol-
ism might be an attractive therapeutic target, since signals
from VEGF and other pro-angiogenic factors would cen-
trally converge onto metabolism. In the likely event that
cancer cells overcome inhibition of VEGF by upregulating
other pro-angiogenic signals to bypass anti-VEGF therapy,
metabolism remains the downstream target to increase
EC proliferation for angiogenesis (Figure 1). Hence, tar-
geting EC metabolism might offer unprecedented oppor-
tunities for the development of alternative antiangiogenic
therapies.
In contrast to the vast literature on angiogenesis
(nearly 50,000 papers have been published on VEGF
alone), only a handful of papers have been published on
how ECs adapt their metabolism when shifting from
quiescence to rapid growth during vessel sprouting.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Rationale to target EC metabolism—a hypothesis. Figure top: With time, the conventional anti-VEGF antiangiogenic treatment suffers
from increasing resistance due to a shift towards alternative pro-angiogenic molecules of potentially various origins. Figure bottom: The antimetabolism
treatment bypasses this problem by targeting the PFKFB3 protein downstream of the angiogenic signaling pathways. The blockage of PFKFB3 with
3PO results in a reduction of glycolysis levels and a subsequent halt of the angiogenic process. 3PO 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one,
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, VEGF vascular endothelial growth factor, VEGFR2 vascular endothelial growth factor
receptor 2.
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ECs in vitro without any further insight on the impor-
tance of such changes for vessel growth in an intact
organism or whether they can be targeted for antiangio-
genic therapy. Emerging evidence indicates, however,
that EC metabolism is an important determinant of EC
phenotypes and behavior and a viable target for antian-
giogenesis. Before describing our current understanding
of EC metabolic adaptations, we will first provide a brief
overview on the fundamentals of vessel sprouting.
Angiogenesis: the basics of vessel sprouting
In healthy adults, ECs remain quiescent for years. How-
ever, these cells can very rapidly start to proliferate and
migrate to form new vessels in conditions of injury,
inflammation, cancer, or other pathologies. Vessel sprou-
ting in mammals is a highly coordinated process, relying
on a migratory (but non- or rarely proliferative) tip cell,and trailing proliferating stalk cells, elongating the sprout
shaft (Figure 2A). In the current model (Figure 3A), ge-
netic regulation of angiogenesis involves signaling through
VEGFR2, the receptor for the pro-angiogenic factor VEGF
[8]. Briefly, VEGFR2 signaling activates the expression of
Dll4 on the surface of tip cells. Dll4 is a ligand for the
Notch receptor expressed in neighboring stalk cells. Acti-
vation of Notch is a potent pro-stalk cell signal in part by
downregulation of VEGFR2 and other VEGF coreceptors
(like neuropilin-1) and upregulation of VEGF inhibitors
(like the VEGF trap VEGFR1) in stalk cells. By activating
Notch signaling in neighboring cells, a tip cell thus en-
sures that it is flanked by stalk cells [9]. In this feedback
system, tip cells promote neighboring ECs to assume the
stalk cell phenotype in an effect known as lateral inhi-
bition (Figure 3A).
An exciting discovery was that tip and stalk cells are
not genetically predetermined, irreversible cell fates, but
Figure 2 PFKFB3 blockade reduces angiogenesis. (A) Current model of vessel sprouting, relying on a migratory tip cell with filopodia that
competes for the tip position. Proliferating stalk cells elongate the sprout. Once perfused, ECs turn into quiescent phalanx cells. (B) Blocking
PFKFB3 results in impaired proliferation and migration of endothelial stalk and tip cells, respectively, and impedes the dynamic overtaking of ECs
typically seen during physiological angiogenesis, all resulting in impaired vessel sprouting. Adapted from [157].
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notypes. Tip cells do not remain at the tip for extended
periods of time, but continuously shuffle as ECs compete
for the position at the tip [10]. Indeed, cells are seen
to overtake each other, with cells moving towards or
away from the tip [10]. During this movement, cel-
lular VEGFR1 and VEGFR2 levels are continuously re-Figure 3 Glycolysis compartmentalization for cell motility. (A) Model o
upregulation of Dll4. Activation of Notch on neighboring ECs by Dll4 gene
expression of VEGFR2 and thereby specifies this cell into a stalk cell. Activat
glycolysis. Note that glycolytic enzymes and glycolytic ATP production are
where they interact with the actin cytoskeleton. (B) In cancer cells, glycolyt
(C) Likewise, glycolytic enzymes are present at higher levels in the motile t
suggesting that glycolysis mediates rapid movements of these structures.adjusted to account for the changes in Dll4 expression
in neighboring cells. Thus, the tip-stalk cell pattern is a
dynamic shuffle among competitive ECs. Until recently,
only genetic signals were known to specify the tip versus
stalk cell identity, but recent evidence indicates that
metabolism is also a key determinant of the EC subtype
specification (see below). Whether ECs cannot stay atf lateral inhibition: activation of VEGFR2 in the tip cell by VEGF induces
rates the signaling Notch intracellular domain (NICD), which lowers
ion of VEGFR upregulates the expression of PFKFB3 and increases
localized and concentrated in the lamellipodia and filopodia of ECs,
ic enzymes are also concentrated in invasive invadopodia.
ail of sperm cells or in motile predatory tentacles of the hydra,
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deprived from nutrients when migrating into an avascular
milieu is an intriguing but outstanding question.
During maturation of newly formed vessels, EC secre-
tion of PDGF-B and other signals attracts PDGFR-β
expressing pericytes in order to stabilize and functionalize
nascent vessels [11]. Mural cell coverage contributes to
vessel maturation and induces ECs to once again become
quiescent phalanx cells, a process relying on angiopoietin-
1/Tie2 signaling, the PHD2 oxygen sensor, junctional
molecules (VE-cadherin, claudins, etc.), and other signals
[2,12].
The full repertoire of signaling pathways involved
in the regulation of angiogenesis is not within the
scope of this review and has been reviewed elsewhere
[1,8,9,12-14]. Nevertheless, it is worthwhile to emphasize
that the complexity of these pathways complicates
current attempts to block tumor angiogenesis. For in-
stance, blockage of VEGF evokes escape mechanisms of
tumor revascularization by promoting the release of
additional pro-angiogenic signals [2-5].
The tumor microenvironment: a metabolic challenge
The microenvironment in tumors greatly differs from
that in healthy tissues. In tumors, vessels are charac-
terized by abnormal structure and function [12,15]. They
are dilated, tortuous, and hyperpermeable as caused by
irregularities in each of the layers of the vessel wall. ECs
are poorly connected and lack a regular pattern. The
basement membrane has non-uniform thickness and
composition, and mural cells are less abundant and
detached. These conditions cause impaired oxygen and
nutrient delivery, itself a potent trigger of angiogenesis,
thereby leading to a self-reinforcing effect on tumor
vessel growth and vascular plexus malformation. For the
same reasons, chemotherapy drug delivery is diminished.
The defective mural cell coverage also increases the
possibility of metastasis [12,15].
Because of its dysfunctional tumor vasculature, cancer
cells are deprived of nutrients. Within the tumor intersti-
tium, oxygen is more limiting than glucose. Compared to
glucose, oxygen has a higher diffusion coefficient, but
lower solubility and therefore also a lower available tissue
concentration. The result is a shorter diffusion distance
and steeper concentration gradient from the vessel to the
tissue [16-18]. As a consequence, cancer and stromal cells
alike activate hypoxia signaling through stabilization of
HIF-1α, which induces a plethora of adoptive metabolic
changes, switching cancer cell metabolism away from oxi-
dative phosphorylation to glycolysis, increasing glycogen
synthesis, and shifting from glucose to glutamine as the
major substrate for fatty acid synthesis [19,20]. The role of
HIFs in adaptive metabolic changes in ECs remains poorly
characterized. Nonetheless, which regulatory machineryECs use to adapt their metabolism remains a relevant
question since ECs, unlike many other cell types, must be
able to function optimally in oxygen/nutrient-deprived
conditions when vascularizing avascular tissues.
A matter of growing importance is to understand how
the tumor microenvironment responds to antiangiogenic
treatments and the impact this has on the metabolism of
cancer and endothelial cells alike. Because current antian-
giogenic agents prune tumor vessels, they increase tumor
hypoxia and deprive cancer cells from nutrients. As a re-
sult, cancer cells turn more to non-oxidative metabolism,
which could contribute to the selection of resistant cancer
clones [21]. A compelling observation is that antiangio-
genic treatment can induce persistent metabolic changes
in cancer cells (i.e., suppression of mitochondrial bio-
genesis and hyperactive glycolysis) [22]. Whether this
reflects epigenetic reprogramming of metabolism with
long-lasting effects is unknown but certainly deserves in-
vestigation. An alternative therapeutic paradigm relies on
tumor ‘vessel normalization,’ which restores at least in part
the normal structure and function of tumor vessels,
thereby improving the supply of oxygen and nutrients
[12,15]. Emerging evidence indicates that this lowers
glycolytic adaptations of cancer cells [23], but the conse-
quences for EC metabolism still remain unknown.
Cancer and endothelial metabolism: brothers in arms
Cancer cells and ECs not only reciprocally stimulate
each other's growth, but together, they also promote
tumor growth. Blood vessels nourish the metabolically
demanding cancer cells, while cancer cells enhance
metabolism of ECs through releasing pro-angiogenic sig-
nals, thereby promoting vessel growth and, in a positive
feed-forward loop, also their own growth. This interplay
between both cell types provides an attractive target for
antitumor strategies. Understanding the metabolic pecu-
liarities of endothelial and cancer cells and the simi-
larities and differences in metabolism between ECs,
necessary for tumor growth on one hand, and cancer
cells, driving tumor growth on the other hand, may lead
to innovative strategies for targeting the factors that
fuel aggressive cancer progression. In contrast to the
ever-growing knowledge about cancer cell metabolism
[24-27], EC metabolism has been studied much less.
However, interest in understanding EC metabolism in
health and disease is rapidly mounting with innovative
technological capabilities and emerging concepts.
The recent discovery that vessel sprouting is determined
by metabolic regulation (see below) offers novel thera-
peutic opportunities to synergize with current anticancer
therapies or circumvent their shortcomings. Conversely,
the recognition that cancer cells adopt their metabolism
in response to antiangiogenic treatment and the possibility
that cancer cell resistance against antiangiogenic agents
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the viewpoint that both cell types are closely intertwined
and depend on each other [21]. Since cancer cells repre-
sent a widely heterogeneous group of cells that rely on
multiple types of metabolic adaptations [24-27], even
within a single tumor type [28], we will for reasons of
brevity not provide an in-depth overview of all possible
metabolic alterations in different cancer cell subtypes.
Rather, focusing on endothelial metabolism, we will more
briefly highlight how metabolism is altered in cancer cells
for each of the metabolic pathways discussed in ECs by
illustrating key principles and providing selected exam-
ples. A schematic of the metabolic pathways discussed
and their specifics in endothelial versus cancer cells is
illustrated in Figure 4.
Glycolysis
Most cancer cells are highly glycolytic. Even when suffi-
cient oxygen is available for oxidative glucose metabolism
and despite the fact that per mole glucose, much less ATP
is generated via glycolysis than glucose oxidation; cancer
cells prefer ‘aerobic glycolysis,’ an observation known as
the Warburg effect [29,30]. Notably, the tumor suppressor
p53, genetically inactivated in many cancers, regulates
several metabolic pathways including glycolysis [31]. For
instance, p53 suppresses the expression of the glucose
transporters GLUT1 and GLUT4 [32] and the glycolytic
enzyme phosphoglyceromutase [32,33]. At the same time,
p53 not only upregulates TIGAR, an inhibitor of glycolysis
that stimulates the oxidative pentose phosphate pathway
(oxPPP), but also transactivates cytochrome c oxidase 2
(SCO2), required for the assembly of subunit 2 of the
cytochrome c oxidase respiratory complex, essential for
mitochondrial respiration [34,35].
In conditions of energy stress, cancer cells use glyco-
lysis for ATP production by relying on pyruvate kinase
(PK)-M1, but when they are actively dividing, they switch
to PKM2, which diverts glycolytic intermediates into
biosynthetic and redox side-pathways (Figure 4B) [36-38].
Indeed, the gene encoding phosphoglycerate dehydro-
genase (PHGDH), the rate-limiting enzyme of the serine
biosynthesis pathway, is amplified in breast cancers and
melanoma [39,40]. Upregulation of PHGDH diverts the
glycolytic intermediate 3-phosphoglyceric acid to the
serine biosynthesis pathway [40]. Serine can be incorpo-
rated into proteins or shuttled into the glycine synthesis
pathway and further towards pyrimidine metabolism.
Glycine decarboxylase (GLDC), an enzyme upregulated in
several cancers, can drive the flux from serine to pyrimi-
dine synthesis [41], but recent evidence indicates that
serine, not glycine, supports cancer cell proliferation [42].
Similarly, the PPP and the hexosamine biosynthesis
pathway (HBP) use glucose for anabolism and protein
glycosylation (see below) [40,43-46].ECs resemble cancer cells in their preferential use of
glycolysis. Endothelial phalanx cells are said to be in a
quiescent state because they do not proliferate, and can
remain quiescent for years in vivo. From a metabolic
point of view, however, this term is misleading as phal-
anx ECs are anything but metabolically quiescent, and
require a substantial baseline glycolysis flux, compared
to other quiescent cell types (e.g., quiescent immune
cells), in order to function as an endothelium and main-
tain vascular barrier homeostasis [6]. ECs generate most
of their energy through glycolysis [6,47-49] and blocking
glycolysis with 2-deoxy-D-glucose (2DG) is toxic for ECs
[50,51]. This seems counterintuitive at first, since ECs
are in immediate contact with blood, an almost limitless
source of oxygen and glucose and thus an ideal environ-
ment for oxidative phosphorylation (OXPHOS). ECs are
however very plastic cells, and after long-term quies-
cence, they can start to proliferate rapidly in response to
pro-angiogenic stimuli like hypoxia, VEGF, and other
signals. We postulated that this angiogenic switch would
require a metabolic switch to meet the increased ener-
getic and biosynthetic demands of sprouting ECs to
form new blood vessels. Indeed, upon vessel sprouting,
ECs nearly double their glycolytic flux [6].
There are several hypothetical reasons why ECs would
choose glycolysis over OXPHOS. First, by abstaining
from the use of oxygen, ECs preserve the high concen-
trations of oxygen in the blood for the cells of the tissue
they perfuse. Second, oxidative metabolism generates
reactive oxygen species (ROS). By using glycolysis, ECs
protect themselves and perivascular cells from oxidative
stress, in an environment that is already exposed to high
levels of oxygen. Third, sprouting ECs migrate through
areas of hypoxia. Using an oxygen-independent type
of metabolism allows ECs to move from normoxic to
hypoxic areas without major adaptations to their meta-
bolism. Indeed, hypoxia is known to induce glycolysis
further [52] and upregulate glycolytic enzymes such as
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and others in ECs [53,54]. Fourth, although OXPHOS
generates higher amounts of ATP per mole of glucose,
glycolysis can actually produce ATP faster, and thus
generate comparable amounts of ATP as oxidative me-
tabolism of glucose as long as there is a sufficient supply
of glucose [30,55,56]. Thus, a high rate of glycolysis can
account for the high metabolic demand necessary for
migration and proliferation of ECs during vessel sprout-
ing. A last possible reason why ECs rely on glycolysis
could be that glycolysis branches off into macromolecule
synthesis pathways. Similar to cancer cells, high gly-
colysis could allow ECs to maintain these pathways
for biomass production and proliferation, necessary for
angiogenesis. Pro-angiogenic signaling can indeed regu-
late the flux through glycolysis, the PPP and glycogen
Figure 4 (See legend on next page.)
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Figure 4 Endothelial versus cancer metabolism. Highlights of some common and distinct features of key metabolic pathways displayed by
endothelial cells (A) and cancer cells (B). 1,3BPG 1,3-bisphosphoglyceric acid, 2PG 2-phosphoglycerate, 3PG 3-phosphoglycerate, Acetyl-CoA
acetyl-coenzyme A, eNOS endothelial nitric oxide synthase, F1,6P2 fructose 1,6 bisphosphate, F2,6P2 fructose 2,6 bisphosphate, F6P fructose 6-phosphate,
FA fatty acid, FABP fatty acid binding protein, FATP fatty acid transfer protein, G1P glucose 1-phosphate, G3P glyceraldehyde 3-phosphate, G6P glucose
6-phosphate, G6PD glucose-6-phosphate dehydrogenase, GAPDH glyceraldehyde 3-phosphate dehydrogenase, GFAT glutamine-fructose-6-phosphate
transaminase, GlcN6P glucosamine-6-phosphate, GLDC glycine decarboxylase, GLS glutaminase, GLUT glucose transporter, Gly glycine, GS glutamine
synthetase, NADP+/NADPH nicotinamide adenine dinucleotide phosphate, NO nitric oxide, OXPHOS oxidative phosphorylation, PC pyruvate carboxylase,
PEP phosphoenolpyruvate, PFK phosphofructokinase, PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, PGAM phosphoglycerate mutase,
PHGDH phosphoglycerate dehydrogenase, PK pyruvate kinase, PPP pentose phosphate pathway, R5P ribose 5-phosphate, ROS reactive oxygen species,
Ru5P ribulose 5-phosphate, SCO cytochrome c oxidase, Ser serine, TCA tricarboxylic acid, TKT transketolase, TKTL transketolase-like protein, UDP-GlcNAc
uridine diphosphate N-acetylglucosamine, VEGFR2 vascular endothelial growth factor receptor 2.
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labeling studies are required to map the anabolic meta-
bolism of angiogenic ECs.
Phosphofructokinase-2/fructose-2,6-bisphosphatase 3
(PFKFB3) is a stimulator of glycolysis. One of the rate-
limiting steps of glycolysis, the conversion of fructose-6-
phosphate (F6P) to fructose-1,6-bisphosphate (F1,6P2) by
6-phosphofructo-1-kinase (PFK-1) is enhanced by the
allosteric coactivator fructose-2,6- bisphosphate (F2,6P2),
the product of PFKFB3 [6]. PFKFB3 and glycolysis are up-
regulated by the tip cell signal VEGF and downregulated
by the stalk cell signal Notch in ECs [6] (Figure 3A).
Hence, glycolysis levels are believed to be higher in tip
than stalk cells in the growing vessel sprout, even though
glycolysis in stalk cells is also necessary for proliferation of
these cells. VEGF also upregulates the expression of facili-
tated glucose transporter type 1 (GLUT-1), increasing glu-
cose uptake [58]. Thus, it seems that angiogenic signaling
factors regulate metabolism, a finding that fits well with
the hypothesis that ECs must adapt their metabolism to
fuel migration and proliferation during angiogenesis. In an
in vitro angiogenesis model, silencing of PFKFB3 reduces
glycolysis and vessel sprouting, whereas overexpression
of PFKFB3 induces opposite effects [6]. Moreover, EC-
specific deficiency of PFKFB3 inhibits vessel growth and
causes vascular defects in several in vivo models of angio-
genesis. This is due to impaired stalk cell proliferation and
tip cell migration (Figure 2B). In fact, PFKFB3 knockdown
not only negatively influences tip cell selection, but also
abrogates increased tip cell competence upon Notch silen-
cing in vitro [6]. PFKFB3-driven glycolysis can even over-
rule the potent pro-stalk cell effect of Notch signaling and
render stalk cells sufficiently competitive to reach the tip
in an in vivo zebrafish model of vessel sprouting. Hence,
glycolysis is capable of cospecifying the tip versus stalk cell
identity of ECs during sprouting and can overrule genetic
angiogenic signals.
Interestingly, when staining for PFKFB3 and other
glycolytic enzymes, their presence was localized in the
perivascular cytosol in quiescent contact-inhibited ECs,
but was also detected at the membrane ruffles in lamelli-
podia of migrating ECs, i.e., at the very cytoskeletalprotrusions that pull ECs forward [6]. PFKFB3 co-stained
with F-actin in membrane ruffles of lamellipodia at
‘hotspots’ of ATP generation. These data led to the hy-
pothesis that glycolytic enzymes maintain lamellipodia
motor activity necessary for migration by forming
‘glycolytic hubs’, for the local generation of ATP in
lamellipodia. Notably, mitochondria are too bulky and
therefore excluded from the thin lamellipodia and tiny
filopodia. In agreement, inhibition of mitochondrial
respiration does not affect vessel sprouting in vitro, sug-
gesting that mitochondrial ATP production is unneces-
sary for this process [6]. Together, these findings identify
glycolysis as an important regulator of angiogenesis,
tightly intertwined with genetic angiogenic signals. Like
for many cancer cells, the glycolysis addiction of ECs
makes this pathway a target for antiangiogenic therapy
(see further below) [7,59,60].
Of note, the relationship between glycolysis, cellular
cytoskeleton, and motility may be of more general im-
portance than originally expected (Figure 3). Indeed,
glycolytic enzymes are also enriched in tumor invado-
podia [61-65]. Moreover, glycolytic enzymes have been
associated with structures for rapid movement functions
such as in hydra tentacles and sperm flagella (Figure 3C)
[66,67], and localized glycolytic machinery may supply
constant energy, independent of mitochondria, for the
persistent movement of vesicles over long distances in
axons [68]. In addition, in transgenic fruitflies, failure of
glycolytic enzymes to colocalize in actin-rich sarcomeres
results in the inability to fly, even though the full com-
plement of active glycolytic enzymes is present in flight
muscles [69]. The selective preference of glycolysis and
its compartmentalization in structures involved in rapid
movements are supported by findings in the hydra that
the more slowly advancing movements of its body over
the sea floor relies on oxidative metabolism, while the
rapid and dynamically changing movements of its tenta-
cles necessary for praying require anaerobic glycolysis.
Pentose phosphate pathway
Other metabolic pathways are important for cellular
processes and may play important roles in regulating
Verdegem et al. Cancer & Metabolism 2014, 2:19 Page 8 of 19
http://www.cancerandmetabolism.com/content/2/1/19angiogenesis, but their role remains understudied. The
pentose phosphate pathway (PPP) is a metabolic pathway
necessary for redox homeostasis whose starting substrate,
glucose-6-phosphate, is a glycolytic intermediate. There
are two branches to the PPP. The oxidative PPP (oxPPP)
produces NADPH and ribose-5-phosphate (R5P), whereas
the non-oxidative PPP (non-oxPPP) only produces R5P in
a reversible manner. Glucose-6-phosphate dehydrogenase
(G6PD) is a rate-limiting enzyme of the oxPPP, while
transketolase (TKT) fulfills this role for the non-oxPPP.
Transketolase-like 1 (TKTL1), a poorly studied homo-
logue of TKT, also has transketolase activity [70,71].
NADPH can be used for the conversion of oxidized gluta-
thione (GSSH) to reduced glutathione (GSH) by gluta-
thione reductase. GSH is a key antioxidant in the defense
against damaging reactive oxygen species (ROS). NADPH
is also required for lipid and nitric oxide (NO) synthesis,
whereas R5P is an essential carbon source for ribose pro-
duction, used for nucleotide synthesis. Thus, the PPP can
be used by cells as an anabolic pathway to generate bio-
mass for proliferation or to bolster an antioxidant defense
in conditions of oxidative stress [44,46,72,73].
Because the PPP is important for nucleotide synthesis
and redox homeostasis, it is typically upregulated in re-
sponse to oxidative stress or in rapidly proliferating cells,
both in healthy tissue and cancer cells. TKTL1 has been
suggested as a biomarker for aggressive cancer types and
correlates with metastasis [74,75]. It is required for rapid
growth and viability of tumor cells [76] and protects
against apoptosis induced by growth factor withdrawal,
oxidative stress, or cytotoxic therapy, while TKTL1 silen-
cing hinders tumor cell proliferation [76,77]. In vivo,
silencing of tumor cell TKTL1 reduces tumor growth,
while overexpression of TKTL1 has opposite effects
[78,79]. The tumor suppressor p53 binds and inhibits
G6PD of the oxPPP; hence, p53 loss in cancer cells
would provide them a growth advantage by increased
oxPPP-dependent redox buffering or biomass produc-
tion [80]. It has been suggested that deregulation of the
PPP in cancer cells could be causative to tumor pro-
gression [81]. Upregulation of key PPP enzymes such as
G6PD increases cancer cell proliferation in vitro [82].
Additionally, the PPP may regulate tumor cell death and
apoptosis by regulating GSH and ROS levels, and similar
associations have been made with increased chemo and
radiotherapy resistance [81,83].
For ECs too, there are several indications that the PPP
plays a regulatory role in cell behavior and angiogenesis.
First, as an important source of NADPH, the oxPPP
contributes to synthesis of the pro-angiogenic signal NO
by providing NADPH as cofactor for the endothelial NO
synthase (eNOS), [84]. In ECs, overexpression of G6PD
increases NADPH and NO levels [84]. Therefore,
the oxPPP activity may promote angiogenesis throughsynthesis of NO, which is known to modulate EC func-
tion [85,86]. Second, G6PD seems to directly modulate
VEGFR2 signaling in a positive manner. Silencing of
G6PD decreased VEGF-induced EC proliferation, mi-
gration, and tube formation in vitro [87]. In ECs, G6PD
association with the membrane is increased upon VEGF
stimulation, suggesting a signaling function of G6PD,
downstream of VEGF [88]. Moreover, silencing of G6PD
reduced the phosphorylation of VEGFR2 and downstream
Akt [87]. The translocation of G6PD to the membrane
was in part mediated by G6PD phosphorylation by the
tyrosine kinase c-src [88]. Upon abolishing G6PD phos-
phorylation by mutation of the phosphorylation site,
VEGF-mediated Akt phosphorylation and EC migration
was reduced [88].
The PPP also regulates redox homeostasis in ECs, and
thereby can influence cell viability and angiogenesis. First,
downregulation of G6PD increases ROS levels in ECs [89],
while conversely, overexpression of G6PD in ECs atte-
nuates the ROS response [84], implying that the PPP has a
protective function against oxidative stress in ECs, neces-
sary for vessel maintenance and homeostasis. This is espe-
cially relevant in diabetes, as one of the effects of high
glucose levels on ECs is an increase in oxidative stress.
Hyperglycemia-induced ROS in ECs contributes to dis-
organization of the vasculature and atherosclerosis [90].
Also, hyperglycemia-induced vascular damage is in part
mediated by downregulation of G6PD, resulting in a re-
duction of NADPH levels [91]. A second consequence of
the activity of the PPP in redox balance is that it can nega-
tively affect angiogenesis (thus, in contrast to the above-
mentioned positive effects). Indeed, since ROS can have
dual effects on angiogenesis and can mediate pathological
angiogenesis [92], it is conceivable that by replenishing
GSH, PPP-derived NADPH may negatively influence
angiogenesis. This may explain why patients with heredi-
tary G6PD deficiency have increased vascular retinopathy,
a complication from diabetes [93]. Overall, most data
implicate a pro-angiogenic effect of the PPP, though an
angiostatic activity has also been reported, indicating that
its effects on angiogenesis can be context dependent.
Hexosamine biosynthesis pathway
The hexosamine biosynthesis pathway (HBP) produces
uridine-diphosphate-N-acetylglucosamine (UDP-GlcNAc)
used for O- and N-linked glycosylation necessary for
normal protein activity [94,95]. Glutamine:fructose-6-
phosphate transaminase (GFAT) converts fructose-6-
phosphate and glutamine into glucosamine-6-phosphate
(GlucN6P) in the HBP rate-limiting reaction. Subsequent
reactions require acetyl-CoA and ATP to produce UDP-
GlcNAc, which is then used for O- or N-linked gly-
cosylation. Indeed, glycosylation is a common protein
modification and has functional implications in nutrient
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cells [96]. Accordingly, the HBP has been suggested as a
potential target to modulate cancer cell proliferation [97].
In a pancreatic tumor model, inhibiting the oncogene
Kras decreases GFAT expression, HBP flux, and subse-
quent protein glycosylation [46]. The reduced HBP flux
and protein glycosylation, coupled with reduced non-
oxPPP flux, lead to decreased tumor volumes, suggesting
that heightened HBP flux may be required to maintain
cancer cell state [46]. Still, the functional significance of
the HBP flux during angiogenesis is not well characterized
and the specific endothelial pathways influenced by glyco-
sylation are not well understood.
ECs cultured in high glucosamine concentrations in-
crease protein glycosylation and reduce migration and
tube formation [98]. Furthermore, sprouting from cul-
tured aortic rings is impaired under high glucosamine
conditions, possibly by Akt glycosylation [98]. Overexpres-
sion of O-GlcNAcase, which reduces glycosylation by
cleaving the O-GlcNAc modifications [99], increases EC
migration and tube formation [98]. Altering N-linked
glycosylation has also been suggested to impair EC angio-
genic functions in vitro, but continued investigation is
necessary for confirmation [50]. By binding the glyco-
sylated regions of VEGFR2, the glycan binding protein
galectin-3 increases its angiogenic activity, presumably by
promoting VEGFR2 localization to the EC membrane
[100]. VEGFR2 glycosylation and binding by galectin-1 is
also responsible for continuous VEGFR2-mediated angio-
genic activity independent of VEGF after anti-VEGF treat-
ment in refractory tumors. In addition, genetic ablation of
glycosyltransferase, an enzyme involved in VEGFR2 glyco-
sylation in ECs, decreases tumor-associated angiogenesis
and tumor growth [101]. Another key angiogenic receptor
that is glycosylated is Notch, which enhances its angio-
static activity [102]. Current information on the HBP and
glycosylation in ECs indicates their importance in regu-
lating both EC activation and inhibition, but the specific
pathways and mechanisms involved in angiogenesis are
not well characterized.
Tricarboxylic acid cycle and oxidative phosphorylation
Oxidative phosphorylation (OXPHOS) is an aerobic
metabolic process within mitochondria whereby pro-
ducts from the tricarboxylic-acid (TCA) cycle, fatty acid
β-oxidation, and amino acid oxidation contribute elec-
trons to the electron transport chain (ETC) to produce
ATP from ADP. According to the Warburg hypothesis,
cancer cells prefer to generate ATP by metabolizing glu-
cose into lactate rather than breaking down pyruvate
through oxidative steps. Generally, the hypoxic tumor
milieu stabilizes HIF-1α whose downstream transcrip-
tional targets increase expression of glycolytic enzymes,
presumably to shift away from dependence on oxygenconsumption [20]. Mutations to mitochondrial DNA in
cancer cells may also contribute to the switch towards
glycolytic dependence [103]. Nonetheless, some cancers
maintain their oxidative capacity, suggesting that cancer
cell types exhibit great differences in their TCA and
OXPHOS activity in a context-dependent manner [27,104].
In some cases, oncogenic mutations of TCA or ETC
genes drive tumorigenesis. Examples include mutations of
fumarate hydratase or succinate dehydrogenase, which
truncate the TCA cycle, leading to build up of metabolites
that increase pro-tumorigenic HIF-1α stabilization
through inhibition of the oxygen sensing prolyl hydroxy-
lases [105,106]. Another example is mutant isocitrate de-
hydrogenase, which generates a so-called oncometabolite
called 2-hydroxy-glutarate that may participate in tumor
progression [107-109]. However, 2-hydroxy-glutarate and
its definitive role in cancer remain incompletely under-
stood. While certain cancer cells have reduced TCA and
ETC activity, others show altered TCA activity. In hyp-
oxia, some cancer cell lines exhibit reductive carboxyl-
ation of α-ketoglutarate (α-KG) to sustain cell viability
[110-113]. Cancer cells also have altered means to replen-
ish the TCA cycle, for instance via pyruvate carboxylase
(PC) or enhanced levels of glutaminase (GLS) driven by
Myc expression [114,115]. As explained below, stressed
cancer cells rely on FAO to produce ATP for survival or
NADPH for redox homeostasis to counter high oxidative
stress levels in these cells. Mitochondrial dysfunction has
also been associated with antiapoptotic cancer cell pheno-
types [116]. Support for this association stems from evi-
dence that several mutations in the ETC, which mediates
a key apoptotic pathway, contribute to cancer cell survival
[117]. Thus, a plethora of alterations in oxidative meta-
bolism contribute to tumorigenesis.
The role of mitochondria in ECs remains open for
extensive research. Most ECs (except those of the
blood–brain barrier) contain active mitochondria that
compose less than 5% of the cell volume, in general far
fewer than in other cell types [118-120]. Although glu-
cose oxidation coupled to OXPHOS is at least 20-fold
more efficient than glycolysis in producing ATP per
mole of glucose and ECs have immediate access to oxy-
gen, less than 1% of pyruvate is oxidized through the
TCA cycle by ECs in vitro, while 99% is converted to
lactate through glycolysis [6]. This may explain why oxi-
dative pathways contribute only a small amount of ATP
for EC function and why blocking the ATP synthase of
the ETC by oligomycin did not impair lamellipodia pro-
duction of ATP and vessel sprouting from EC spheroids
[6]. Similar to cancer cells, ECs have a relatively limited
amount of oxygen consumption through OXPHOS [6].
In culture, ECs use only about 35% of their total oxida-
tive capacity [121], but can reserve oxidative capacity
and increase glucose oxidation for conditions of high
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is limited [121-123].
Alternatively, aside from their bioenergetic function, EC
mitochondria have also been implicated in signaling.
Mitochondria-derived ROS, primarily superoxide anion
produced through the electron transport chain, and ROS
generated by the enzyme NADPH oxidase act as pro-
angiogenic signaling molecules at non-toxic concentra-
tions [124,125]. Besides hemodynamic forces and cyclin
strain, VEGF increases mitochondria biogenesis and sti-
mulates mitochondrial metabolism and ROS production
of ECs in vitro [126-130], suggesting that mitochondrial
OXPHOS may play a role in angiogenesis [131]. Indeed,
ROS have been shown to mediate VEGFR2 phospho-
rylation through inactivation of tyrosine phosphatase ac-
tivity, highlighting the link between redox control and
angiogenesis [132-134]. Through inhibition of the PHD
oxygen sensors, ROS activate HIFs, which enhance angio-
genesis and glycolytic metabolism supporting this process
[135]. ROS can also directly activate pro-angiogenic
growth factor receptor or other molecules through oxida-
tion of susceptible cysteine residues [134]. Interestingly,
ROS-dependent phosphorylation has also been implicated
in modulating both in a positive- and negative-manner EC
junction stability, thus dependent on the cellular context
stimulating angiogenesis or stabilizing vessels [134]. NO,
itself a subtype of ROS, also has various pro-angiogenic
activities on ECs [85,86,136]. In diabetes, ROS generated
by hyperglycemia promotes ligand-independent but Src-
dependent phosphorylation of VEGFR2 within the Golgi
compartment, leading to muted responses to exogenous
VEGF and limiting angiogenic events [137].
Interestingly, glycolysis-derived ATP is in part dedicated
to maintaining the EC mitochondrial network [138], pre-
sumably because these organelles are essential for EC
homeostasis by controlling other processes than meta-
bolism as well. Indeed, mitochondria in ECs mediate Ca2+
storage for its use in signaling for a wide range of phy-
siological cell processes [119]. Moreover, mitochondria
control an apoptotic pathway in ECs, involved in vessel
regression during network remodeling and actively con-
tributing to vascular diseases [139]. In respiring mitochon-
dria, Ca2+ flux through the inner mitochondrial membrane
(IMM) is mainly driven by the IMM potential (ΔΨm) that
establishes a strong electromotive driving force for Ca2+
entry. Hence, mitochondrial respiration is vital for Ca2+
handling and prevention of apoptosis [119,124].
Still, the role of mitochondria and oxidative metabolism
in angiogenesis remains unclear, and the contributions of
mitochondrial ROS versus NADPH oxidase-derived ROS
is unknown [140]. It also remains unknown how ECs
adapt their TCA flow for ATP production, signaling,
redox homeostasis, lipid synthesis, or biomass production.
Additionally, little is known about mitochondria or theiroxidative capacity in tumor-associated ECs. Whether al-
terations to EC mitochondria contribute to aberrant
tumor angiogenesis or a shift in their metabolic status is
not known.
Fatty acid oxidation
Free fatty acids (FFAs) are another energy source that can
be solicited by ECs for the generation of ATP [141]. FFAs
are released into the blood by lipolysis of triglycerides in
the white adipose tissue in times of fasting and can be
stored in the form of triglycerides by the same adipocytes
of the white adipose tissue at times of high-energy avail-
ability [142]. Cancer cells use FFAs as an alternative
energy source when glucose is limiting. For instance,
during loss of adhesion, glucose-uptake is restricted in
cancer cells, and fatty acid β-oxidation (FAO) is activated
in order to maintain ATP production [143]. They can also
consume fatty acids, derived from circulating lipoprotein
particles or supplied by neighboring cancer-associated
adipocytes in a cancer-stromal cell metabolic crosstalk
[144-146]. In cancer cells, FAO is also an important
source of NADPH. FAO produces acetyl CoA, thus
fueling the TCA cycle and subsequent citrate production.
Citrate can be converted to malate or isocitrate, thus
driving malic enzyme or isocitrate dehydrogenase, in both
cases generating NADPH [147]. NADPH is important for
redox homeostasis and serves as a cofactor in numerous
anabolic pathways necessary for biomass production and
proliferation.
FFAs can be used as high-energy source by many
tissues, especially skeletal and cardiac muscle [148], to
which end FFAs are transported across the endothelium.
This process is in part regulated by VEGF-B, a VEGF
family member whose known role in angiogenesis is
limited but not altogether negligent [149]. VEGF-B re-
gulates the expression of fatty acid transport proteins
(FATPs) in ECs, and mice lacking VEGF-B showed re-
duced uptake and accumulation of lipids in perivascular
tissue [150]. The presence of lipid droplets has also been
reported within ECs [151], and the intracellular fatty
acid binding protein 4 (FABP4), important for FFA up-
take and trafficking, seems to be regulated by the main
pro-angiogenic growth factor VEGF [152]. Both intra
and extracellular stores of FFA can be utilized for FAO by
ECs [141]. However, reports on the contribution of FAO
to energy production in ECs are variable [49,153-157], as
this is probably dependent on environmental, genetic, and
metabolic cues.
FAO is induced in ECs by activation of the AMPK sig-
naling pathway upon glucose deprivation [141], possibly
in an attempt to maintain ATP levels when glycolysis
is challenged. Additionally, inhibition of FAO in cancer
cells can increase the vulnerability towards oxidative
stress [158]. It is however unknown whether ECs use
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citrate dehydrogenase, as is seen in cancer cells [159]. If
so, however, replenishment of the antioxidant GSH by
NADPH may affect EC ROS levels, thus influencing
angiogenesis.
Amino acid metabolism
Cancer cells metabolize amino acids for bioenergetic
pathways and biosynthesis. Glutamine is a major source
of cancer cell nitrogen and anaplerosis to replenish the
TCA cycle for biosynthesis [27,160]. Amino acids are
also metabolized by ECs, but the functional significance
of amino acid metabolism is not understood. Glutamine,
also the primary amino acid studied in ECs, can fuel cell
proliferation but its contribution to angiogenesis in vivo
has not been determined. ECs can not only take up
glutamine from the extracellular milieu but can also pro-
duce glutamine from glutamate using glutamine syn-
thetase (GS), though the precise reason is unknown
[161-163]. In the first step of glutamine metabolism, the
conversion of glutamine to glutamate by glutaminase
produces α-ketoglutarate for anaplerosis [26]. Although
the contribution of ATP derived from glutamine oxida-
tion to EC function is unclear, pharmacological blockade
of glutaminase in ECs reduces proliferation and induces
senescence [157,164,165]. When glucose metabolism is
impaired by oxidative stress, glutamine metabolism
contributes more significantly to ATP production [166].
Thus, ECs use glutamine for ATP synthesis depending
on the local environmental conditions. Glutamine me-
tabolism in ECs also contributes carbons for synthesis of
biomolecules and may be a source of nitrogen for orni-
thine synthesis, a precursor of mitogenic polyamines
[167]. Glutamine also inhibits the production of NO by
eNOS [168], and when metabolized to glucosamine, it
inhibits oxPPP flux, which reduces availability of the
eNOS coenzyme NADPH [165,169]. How glutamine me-
tabolism influences EC sprouting in health or disease
has not been described.
Glycogen metabolism
Cancer cells have been shown to sequester and me-
tabolize glycogen in response to hypoxic stress in order
to maintain proliferative capacity [170]. ECs can also
accumulate glycogen derived from glucose or push glu-
cose through the glycogen synthesis pathway, but its role
in EC function is unknown [57]. Glycogen stores are
depleted in ECs under low-glucose conditions, but main-
tained in hypoxia [57]. Thus, ECs may use glycogen as a
backup energy source, perhaps when ECs navigate into
glucose-poor tissue regions. Inhibiting glycogen me-
tabolism also reduces EC viability and migration [57].
Still, glycogen metabolism and synthesis in ECs remains
under-investigated.Endothelial and cancer cell metabolism: different or alike?
The recent surge in data on cancer cell metabolism and
the new insights in EC metabolism have brought their
general similarities, differences, and unknowns into light
(Figure 4).
Commonalities
Certainly, various cancer phenotypes exhibit a wide
range of metabolic characteristics, but the Warburg ef-
fect is considered an overarching feature in many cancer
cells [25,27,104,160]. Similarly, ECs are highly glycolytic,
allowing both cell types to proliferate excessively in the
hypoxic tumor milieu. In fact, glycolytic flux is com-
parable, or even higher in ECs, than in various cancer
cell types [6]. Furthermore, both endothelial and cancer
cells use glycolytic metabolism for similar cellular me-
chanisms, i.e., to regulate their invasive and proliferative
behaviors [6]. They also seem to compartmentalize gly-
colysis in protrusive structures mediating actin cyto-
skeletal rearrangement during cell motility. The reliance
of both cell types on glycolysis implies that this pathway
is an attractive prospect to target both cell types in the
cancer environment (see below).
By contrast, mitochondrial respiration and ATP pro-
duction seem to be less essential for the proliferation of
both glycolytic ECs and most cancer cell types, though
for cancer cells, this varies dependent on metabolic
features. By mediating redox control, the oxPPP is vital
for cellular survival, as is the case for both stressed
endothelial and cancer cells [81,84]. The anabolic ac-
tivity of the PPP for nucleotide synthesis in cancer cells
is likely conserved in proliferating ECs, even though this
has not been formally demonstrated yet. Lipid synthesis,
used for duplication of membranes or production of
signaling molecules, is a characteristic of rapidly proli-
ferating endothelial and cancer cells, and inhibiting this
process impairs both of their proliferation [171,172].
Unlike cancer cells, which are forced to adapt to the
hypoxic tumor milieu that develops around them, ECs are
adjusted to functioning in hypoxic environments while
vascularizing avascular tissue regions. In anticipation of fa-
cing such harsh conditions, ECs store nutrients (glycogen,
lipid droplets) intracellularly. Emerging evidence indicates
that cancer cells have similar capabilities [144,146].
Unknowns
For a number of fundamental metabolic pathways, initial
evidence indicates that ECs may resemble cancer cells,
but available information is insufficient to draw firm
conclusions at this stage. For instance, while it is estab-
lished that glutamine is a major carbon source to replen-
ish the TCA cycle for anabolism in cancer cells [173],
only limited evidence exists that ECs may rely on similar
mechanisms. Also, the capability of hypoxic cancer cells
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reductive carboxylation to synthesize lipids has not been
studied in ECs [110,112]. Remarkably, it remains un-
known if either cell type uses fatty acid-derived carbons
for biosynthesis of macromolecules to sustain cell
proliferation.
Other typical cancer cell metabolic adaptations, such
as their reliance on serine, glycine, and one-carbon me-
tabolism [42], have only minimally or not at all been ex-
amined in ECs. Additionally, the mechanistic details on
how glycolytic enzymes (e.g., PKM1 versus PKM2 [174])
regulate the switch between catabolism and anabolism
have not been documented in ECs, though the import-
ance of others (e.g., PFKFB3) has been illustrated in both
cell types [6,175]. In any case, the differences between
these pathways in endothelial and cancer cells remain to
be further unraveled before their therapeutic potential
becomes apparent.
Differences
ECs and cancer cells also exhibit differences in their
metabolic needs, pathways, and mechanisms. One clear
difference is that in many cases, cancer cells reprogram
their metabolism hardwire. For instance, due to genetic
alterations, cancer cells differ from ECs by switching on
certain metabolic pathways (for instance, serine and gly-
cine metabolism) or inactivating others (for instance,
mitochondrial TCA cycle genes) [176]. On the contrary,
it is unknown if healthy non-transformed ECs with a
stable genome activate such pathways during vessel
sprouting.
Additionally, stressed cancer cells use FAO for redox
protection through production of NADPH and for sur-
vival via generation of ATP [147]. In contrast, ECs do
not rely on FAO for substantial ATP production [6], and
whether they use FAO for redox homeostasis is also un-
clear. Although both cell types use the PPP, endothelial
and cancer cells use it for cell type-specific needs, aside
from generating nucleotides, highlighting its versatility.
For instance, ECs use the PPP to promote angiogenesis,
in part through signaling and NO production, while can-
cer cells use this pathway to promote sustained proli-
feration by securing survival through redox fortification.
Likewise, the multifaceted effects of the HBP explain
why cancer and endothelial cells use this pathway to
meet their context-dependent demands, though the ac-
tive HBP levels indicate the importance of this pathway.
Finally, cancer and endothelial cells differ funda-
mentally in at least one other important aspect, i.e., their
response to nutrient stress or blockade of a critical
metabolic pathway. Indeed, nutrient stress that induces
quiescence and catabolism in normal cells can be lethal
to cancer cells because oncogenic mutations consti-
tutively drive anabolism. Cancer cells are geneticallyreprogrammed to continuously proliferate and thus con-
stantly require large amounts of nutrients for anabolism,
energy production, and redox homeostasis. Hence, if
stressed cancer cells cannot mount an adaptive com-
pensatory metabolic shift, their survival becomes limited.
This addiction to nutrients renders cancer cells vul-
nerable to therapeutic interventions. Recent findings in-
dicate, however, that cancer cells may be able to display
more flexibility than perhaps anticipated. Indeed, a
genetic study showed that cancer cells are capable of
switching from anabolic production of biomass for cell
division to more catabolic ATP generation for survival
in conditions of energy stress [28]. Healthy ECs, by
contrast, can plastically switch back and forth between
quiescence and proliferation and can resort to quies-
cence in conditions of nutrient stress or blockade of a
critical metabolic pathway. Indeed, reducing glycolysis,
which renders rapidly proliferating ECs more quiescent,
sufficed to efficiently inhibit pathological angiogenesis
without induction of compensatory metabolic adaptations,
indicating that induction of quiescence—not necessarily
death—of ECs is a viable therapeutic strategy [7,60].
The link between metabolism and angiogenesis
In light of the metabolic details of ECs provided above
and the description of genetic signaling governing angio-
genesis, an appealing question that arises is in how
far EC metabolism is a determinant of the angiogenic
process and the specification of the EC subtype. There
are indeed several key observations that hint on an im-
portant role for metabolism upstream of the signaling
pathways. For instance, upon VEGF activation of ECs,
they enhance glycolysis through PFKFB3 upregulation
[6]. If this upregulation fails because of PFKFB3 gene
knockout or knockdown, there is a strong impetus for
ECs to abort the switch towards migrating or proli-
ferating states. This is demonstrated by impaired EC
sprouting and filopodia formation in retinal sprouting
vessels and reduced lamellipodia formation in cultured
ECs [6]. More interesting still, the overexpression of
PFKFB3 in mosaic sprouting assays and zebrafish results
in the cells adopting the tip cell phenotype, even in the
presence of potent pro-stalk Notch signaling (transcrip-
tionally active Notch1 domain NICD overexpression)
[6]. This demonstrates that metabolic fitness is an im-
portant regulator of endothelial cell specification.
A second example of metabolism implication in EC
function is found in the situation of nutrient deprivation,
in which case NAD+-dependent deacytelase (SIRT1)
becomes activated [177,178]. SIRT1 deacetylates NICD
causing a reduced NICD stability, making SIRT1 act as a
negative regulator of Notch signaling in ECs [179]. As
such, SIRT1 was found to be crucial for normal vessel
growth, as absence of SIRT1 results in impairment of
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might act as a promoter of vascularization in nutrient-
deprived tissues. Also, SIRT1 is known to deacetylate and
inactivate FOXO1, a negative modulator of angiogenesis
activated upon nutrient stress [180]. Combined, this sug-
gests that a delicate interplay between SIRT1 and FOXO1
is required to coordinate angiogenesis in situations of EC
nutrient deprivation [181].
Furthermore, it has been observed that within a
sprouting blood vessel, ECs dynamically rearrange and
alternate between leading tip cell and trailing stalk cell
positions within the time frame of hours [10,182]. One
hypothesis requiring future confirmation is that tip cells,
being highly active, deplete their energy stores and need
to be replaced by stalk cells with a higher energy profile.
Recently, it was shown using computer modeling that
tip-stalk shuffling can be explained mechanically by dif-
ferential cell-cell adhesion and polarized junctional cor-
tex protrusions [183]. The model suggests that both
processes are dependent on VEGFR and Notch signaling
and parallels the actual in vivo cell adhesion dynamics.
However, one can also speculate about underlying or
overruling metabolic incentives, since PFKFB3-deficient
ECs are found less frequently at the tip position [6].
Metabolism-based antiangiogenic therapy
Angiogenesis is tightly linked to several pathologies. Best
known is the abnormal or excessive angiogenesis con-
tributing to disorders such as inflammation disorders
and cancer [8,184]. From these observations, the con-
cepts of pro- and antiangiogenic therapy have grown, in
an attempt to restore the occurring angiogenic ano-
malies. The classical paradigm for antiangiogenic the-
rapies is the blocking of VEGF or its receptors [185].
However, several issues have limited the success of such
VEGF (receptor)-inhibitor treatment. Indeed, tumors
can rely on other pro-angiogenic factors besides VEGF
or on angiogenic molecules produced by associated stro-
mal cells, making the treatment ineffective [2-5]. The
sustained hypoxic conditions caused by the treatment
can also select for resistant tumor clones. Further me-
chanisms are switches by the tumors to other forms of
vessel growth, besides sprouting angiogenesis, such as
the use of existing vessels (cooption), tumor cell dif-
ferentiation to channels (vascular mimicry), etc. [2-5].
The recent findings on EC metabolism potentially offer
novel antiangiogenic therapeutic opportunities. The
discovery that genetic silencing of PFKFB3 in vitro and its
inactivation in vivo was capable of reducing EC glycolysis
and through this decrease vessel sprouting [157], opened
up a way towards metabolism-based antiangiogenic the-
rapies. Therefore, the small molecule 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3PO), a PFKFB3 inhibitor,
was tested for its antiangiogenic potential [7]. It was foundthat 3PO reduces glycolysis in ECs in vitro with 35–40%
without making them switch to aerobic respiration since
3PO administration was not accompanied by an increase
in oxygen consumption. In vivo glycolysis reduction was
also in the order of 35–40% [7]. The effect of 3PO on gly-
colysis was found to be reversible, as normal sprouting
was recovered after removal in vitro or 6 h after adminis-
tration in vivo. The observed amounts of reduction cor-
respond to the difference in glycolysis activation observed
between quiescent and proliferating or migrating ECs [6],
and can therefore be thought to significantly impair EC
proliferation/migration. In vitro, 3PO indeed considerably
increased the fraction of quiescent ECs at the expense of
proliferating and migrating ECs. However, unlike more ag-
gressive glycolysis blockers such as 2-deoxy-D-glucose
(2DG), which reduces glycolysis to up to 80%, 3PO did
not lead to cell death or unhealthy morphology [7]. Not-
ably, the 3PO phenotype was obtained solely because of a
metabolic effect as typical tip and stalk cell gene ex-
pressions were not altered [7]. In zebrafish embryos,
intersomitic vessel sprouting was impaired in a 3PO dose-
dependent manner, and after withdrawal of 3PO, the
sprouting was reinvigorated. Also, in postnatal mouse
retinas of P1-P4 3PO treated pups, EC proliferation was
impaired [7].
Moving towards pathological angiogenesis and thera-
peutic implications, the following observation becomes
noteworthy. 3PO administration allowed for preventing to
large extent the vascular hyperbranching to occur in
VEGFR1 (an inhibitor of vascular branching) knockdown
zebrafish embryos. When suboptimal doses of 3PO and
suboptimal doses of SU5416, a clinically approved VEGFR
tyrosine kinase inhibitor, were administered in combin-
ation to zebrafish embryos, the angiogenesis impairment
was observed to be larger than those obtained by optimal
doses of the inhibitors independently [7]. Finally, 3PO was
tested in the context of a few angiogenesis-related patho-
logical models. It was administered to mice in which cho-
roidal neovascularization (CNV), a model for age-related
macular degeneration (AMD), was induced by laser burn
injury. Daily 3PO provision resulted in a dose-dependent
reduction of the CNV lesion volume after 14 days, and its
effect was amplified in the case of combined adminis-
tration with DC101 (an anti-VEGFR2 antibody). Upon
hyperoxia-induced capillary depletion in mouse pups
(a model for retinopathy of prematurity), 3PO treatment
reduced the formation of vascular tufts. Also, in two
mouse inflammation models, skin psoriasis, and inflam-
matory bowel disease, 3PO treatment resulted in a re-
duced disease severity [7]. Along this line, PFKFB3
targeting was recently extended to tumor implantation
models [186]. In PFKFB3 knockout mice, tumor size
and weight were significantly decreased as compared
to control mice. Importantly, 3PO is also a viable
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represents a two-pronged attack on cancer progression
[187] (Figure 3). Together, these findings demonstrate that
targeting EC metabolism, and in particular glycolysis and
PFKFB3, can be effective as a therapeutic inhibition of
angiogenesis.
The main advantage that administration of 3PO pro-
vides is its incomplete blocking of glycolysis, since com-
pletely blocking glycolysis may have adverse effect [187].
Although 3PO's short half-life and rapid clearance induce
only transient effects, it remains a promising candidate for
antiangiogenic therapy, alone, or in combination with
other anti-VEGF (receptor) inhibitors because the partial
and transient reduction of glycolysis suffices to inhibit
pathological angiogenesis. This supports a paradigm shift
in our traditional thinking that antiglycolytic therapy
should block glycolysis completely and permanently.
Moreover, the commonalities and differences between
endothelial and cancer cell metabolic characteristics rep-
resent an opportunity for improving tumor therapeutic
strategies.
Conclusions
The close marriage between cancer and endothelial cells,
i.e., cancer cells relying on the vascular supply for meta-
bolic support and growth and ECs relying on cancer cell
release of pro-angiogenic signals for metabolism-driven
angiogenesis, provides a rationale for targeting both cellu-
lar compartments when aiming to block tumor growth.
The metabolic similarities characterized so far between
both cell types suggest that hitting a common metabolic
pathway (like glycolysis) may induce these dual benefits.
Furthermore, the differences between endothelial and can-
cer cell metabolism provide alternative routes to speci-
fically aim at one or the other alone or together. Future
success in designing novel antimetabolism therapies re-
quires monitoring isotope labeling through metabolic
pathways in an unbiased manner and quantitatively identi-
fying fluxes from the data. In addition, recent reports that
metabolism of cancer cells in the culture dish is different,
even opposite, to what has been measured in the intact
tumor in vivo [59,188], necessitates the challenging
characterization of EC metabolism in (tumor) vessels as
well. It has been postulated that unique cancer cell-specific
metabolic pathways should be preferentially targeted to
block cancer growth in order to avoid toxicity on healthy
tissues. However, recent findings indicate that pharmaco-
logically blocking a central metabolic pathway like glycoly-
sis can inhibit pathological angiogenesis without inducing
systemic effects, as long as glycolysis is only partially and
transiently reduced and not completely and permanently
blocked [7,60]. These studies illustrate that not only the
specific metabolic target is important, but the administra-
tion protocols and drug dynamics are critical as well.Another outstanding question is whether targeting EC
metabolism should aim to prune tumor vessels with a risk
of aggravating tumor hypoxia, increasing invasiveness and
metastasis, or rather try to normalize tumor vessels to
reduce metastasis and to improve chemotherapy. In either
case, concomitantly understanding the dynamics of endo-
thelial and cancer cell metabolism will provide avenues
for clinical strategies that more specifically curb excessive
cancer growth, while maintaining necessary vascular
integrity.
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